<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715997</url>
  </required_header>
  <id_info>
    <org_study_id>GX-19N-HV-002</org_study_id>
    <nct_id>NCT04715997</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to evaluate safety, tolerability, and immunogenicity of&#xD;
      COVID-19 preventive DNA vaccine in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is phase 1/2a clinical trial to evaluate safety, tolerability, and&#xD;
      immunogenicity of COVID-19 preventive vaccine by intramuscularly administration in healthy&#xD;
      volunteers.&#xD;
&#xD;
      Phase 1 of this study is designed as single arm, open-labeled and a total of 20 subjects will&#xD;
      be enrolled. Phase 2a of study is designed as randomized, double-blind, placebo controlled&#xD;
      and a total of 150 subjects are planned to be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Solicited Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>solicited local and systemic AEs after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Unsolicited Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>unsolicited AEs after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>percentage of subjects with SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT and GMFR of Antigen-specific Binding Antibody Titers</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>Geometric mean titer (GMT) and Geometric mean fold rise (GMFR) of antigen-specific binding antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Seroconverted After Vaccination</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>Seroconversion defines when FRNT50 is detected more than four times from the baseline after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and GMFR of Neutralizing Antibody Level</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>Geometric mean titer (GMT) and Geometric mean fold rise (GMFR) of neutralizing antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMSN and GMFR of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>Geometric mean spot numbers (GMSN) and Geometric mean fold rise (GMFR) of SFU after vaccination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Antigen-specific IFN-gamma Cellular Immune Response</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>Antigen-specific IFN-γ T cell immune response assessed after vaccination</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>GX-19: Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be intramusculary administered via EP on day 1 and day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-19N</intervention_name>
    <description>DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen</description>
    <arm_group_label>GX-19: Dose A</arm_group_label>
    <arm_group_label>Placebo: Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to comply with all study procedures and voluntarily signs informed&#xD;
             consent form&#xD;
&#xD;
          -  Healthy adult male or female aged 19-55 years&#xD;
&#xD;
          -  Willing to provide specimens such as blood and urine during the study, including end&#xD;
             of study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppresion including immunodeficiency disease or family history&#xD;
&#xD;
          -  Any history of malignant disease within the past 5 years&#xD;
&#xD;
          -  Scheduled to undergo any surgery or dental treatment during the study&#xD;
&#xD;
          -  Having received immunoglobulin or blood-derived drugs or being expected to be&#xD;
             administered within 3 months prior to administration.&#xD;
&#xD;
          -  Having relied on antipsychotic drugs and narcotic analgesics within 6 months before&#xD;
             administration&#xD;
&#xD;
          -  Positive of serology test at screening&#xD;
&#xD;
          -  Suspected of drug abuse or a history within 12 months prior to administration&#xD;
&#xD;
          -  Active alcohol use or history of alcohol abuse&#xD;
&#xD;
          -  Serious adverse reaction to a drug containing GX-19N or other ingredients of the same&#xD;
             categories or to a vaccine or antibiotic, nonsteroidal anti-inflammatory disease&#xD;
             control, etc. or an allergic history&#xD;
&#xD;
          -  History of hypersensitivity to vaccination such as Guillain-Barre syndrome&#xD;
&#xD;
          -  Those who have or with a history of disease corresponding to other hepatobiliary,&#xD;
             kidneys, nervous systems (middle or peripheral), respiratory machines (e.g. asthma,&#xD;
             pneumonia, etc., endocrine systems (uncontrolled diabetes, hyperlipidemia, etc.) and&#xD;
             cardiovascular (congestive heart failure, coronary artery disease, myocardial&#xD;
             infarction, uncontrolled hypertension), blood tumors, urinary machines, mental,&#xD;
             musculoskeletal systems, immune system (rheumatoid arthritis, systemic arthritis,&#xD;
             mumps, immunodeficiency disease)&#xD;
&#xD;
          -  Having hemophilia at risk of causing serious bleeding when injected intramuscularly or&#xD;
             receiving anticoagulants&#xD;
&#xD;
          -  Subjects who have been contact with COVID-19 infections in the past prior to&#xD;
             administration, have been classified as COVID-19 confirmed patients, medical patients&#xD;
             or patients with symptoms or have been identified with SARS and MERS infection history&#xD;
             in the past&#xD;
&#xD;
          -  Acute fever, cough, difficulty breathing, chills, muscle aches, headache, sore throat,&#xD;
             loss of smell, or loss of taste within 72 hours prior to administration&#xD;
&#xD;
          -  Other vaccination history within 28 days prior to the administration or being&#xD;
             scheduled to be inoculated during the study&#xD;
&#xD;
          -  History of having taken immunosuppressant or Immune modifying drug within 3 months&#xD;
             prior to administration&#xD;
&#xD;
          -  Having participated and had clinical trial drug administration in another clinical&#xD;
             trial or biological equivalence study within 6 months prior to the administration&#xD;
&#xD;
          -  Pregnant or breastfeeding female, however, those are allowed to participate in the&#xD;
             study only if they stop breastfeeding before participation (fertile female† must be&#xD;
             negative in serum pregnancy test at screening&#xD;
&#xD;
          -  Fertile female who do not agree to use effective contraception methods (condoms,&#xD;
             contraceptive diaphragm, intrauterine contraceptive devices) during the study&#xD;
&#xD;
          -  Any other clinically significant medical or psychiatric finding which is considered&#xD;
             inappropriate by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JungWon Woo, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genexine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Yong Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon-Jeong Choi, M.S</last_name>
    <phone>82-31-628-3233</phone>
    <email>yoonjeong.choi@genexine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wonjin Lee, B.S</last_name>
    <phone>82-31-628-3278</phone>
    <email>wonjin.lee@genexine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MiSuk Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JunYong Choi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun Joo Pai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungGou Song, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Young Hwa Choi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

